Orographic Financial Advisors LLC Makes New $1.52 Million Investment in Organon & Co. $OGN

Orographic Financial Advisors LLC acquired a new stake in shares of Organon & Co. (NYSE:OGN) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 254,200 shares of the company’s stock, valued at approximately $1,522,000.

Several other hedge funds have also modified their holdings of OGN. Amundi increased its position in Organon & Co. by 84.0% during the first quarter. Amundi now owns 80,944 shares of the company’s stock worth $485,000 after purchasing an additional 36,961 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Organon & Co. by 34.8% during the 1st quarter. California State Teachers Retirement System now owns 327,075 shares of the company’s stock worth $1,959,000 after buying an additional 84,497 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Organon & Co. by 8.5% during the 1st quarter. Royal Bank of Canada now owns 299,663 shares of the company’s stock worth $1,794,000 after buying an additional 23,456 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Organon & Co. by 8.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 52,816 shares of the company’s stock worth $316,000 after buying an additional 3,899 shares during the period. Finally, Infrastructure Capital Advisors LLC boosted its holdings in Organon & Co. by 64.7% in the first quarter. Infrastructure Capital Advisors LLC now owns 28,001 shares of the company’s stock valued at $168,000 after acquiring an additional 11,000 shares during the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Lynette Holzbaur acquired 26,448 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were bought at an average cost of $13.35 per share, with a total value of $353,080.80. Following the completion of the transaction, the senior vice president directly owned 52,851 shares of the company’s stock, valued at $705,560.85. This trade represents a 100.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.62% of the stock is owned by company insiders.

Organon & Co. Stock Performance

Shares of OGN stock opened at $13.54 on Friday. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47. The company has a market cap of $3.56 billion, a PE ratio of 14.56, a P/E/G ratio of 1.25 and a beta of 1.54. The company’s fifty day simple moving average is $13.47 and its 200-day simple moving average is $10.38. Organon & Co. has a 52 week low of $5.69 and a 52 week high of $13.60.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the company posted $1.02 earnings per share. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. As a group, equities research analysts anticipate that Organon & Co. will post 3.23 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on OGN. Weiss Ratings upgraded Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, July 13th. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their price objective for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. BNP Paribas Exane reiterated a “neutral” rating and set a $14.00 target price (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $11.40.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.